Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm Completes Agilent Microarray Service Certification

NEW YORK, Oct. 28 (GenomeWeb News) - Paradigm Genetics and Agilent Technologies said today that Paradigm is the first company to be certified under Agilent's certified microarray service provider program.

The certification builds on a research service relationship that the companies entered in March.

To be eligible for certification, Agilent said that service laboratories must accurately analyze 60-mer microarrays on the complete Agilent gene expression platform, which includes a microarray scanner, hybridization and labeling kits, feature extraction software, and a Rosetta gene expression data analysis system.

The certification "constitutes a formal endorsement from Agilent that we can and continue to provide reliable microarray results that researchers can count on from sample to sample, study to study," said Heinrich Gugger, president and CEO of Paradigm.

Last week, Paradigm announced that it would also provide microarray processing services for the Affymetrix GeneChip platform.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.